FIG. 5.
PTX3 increases the therapeutic efficacy of L-AMB and D-AMB. Bone marrow-transplanted mice, generated as detailed in the legend to Fig. 1, were infected intranasally with 2 × 107 Aspergillus conidia and treated intraperitoneally with each single agent alone or in combination, either before (Pre-) or after (Post-) infection. The dosages were as follows: 0.04 and 0.2 mg of PTX3/kg before or after the infection, respectively; 1 mg of L-AMB and 2 mg of D-AMB/kg. Resistance to infection was assessed in terms of percent survival and fungal growth (CFU) in the lung, determined at the time of death for mice dying earlier or 6 days after the infection. Bars indicate the standard errors. (−, untreated mice). *, P < 0.05, treated versus untreated mice; **, P < 0.001, combined treatment with PTX3 plus L-AMB versus each single treatment alone; ***, P < 0.05, combined treatment with PTX3 plus D-AMB versus D-AMB alone.